Fact Sheet

Jump To:

The Alliance for Regenerative Medicine (ARM) is an international community of small and large companies, non-profit research institutions, patient organizations, and other sector stakeholders dedicated to realizing the promise of regenerative medicine for patients around the world.

Working with our members and policymakers, ARM fosters investment, research & development, commercialization, and access to safe, effective, and transformational treatments and cures.

What Is Regenerative Medicine?

Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.

Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.

The regenerative medicine and advanced therapies sector is creating transformative, durable treatments and potential cures for some of humankind’s most devastating diseases – many currently untreatable via conventional treatments – through the use of ground-breaking scientific discoveries and technologies.

How Does ARM Support the Sector?

ARM takes the lead on the most important issues facing the regenerative medicine and advanced therapy sector today:

 

ARM’s Multi-Stakeholder Membership

Diversity of Organizations (n=290) Diversity of Technology Focus (n=290)
Corporations (Revenue < $50M, <100 FTEs)

54%

Gene Therapy

24%

Corporations (Revenue < $50M, 100 FTEs)

12%

Cell Therapy

29%

Corporations (Revenue > $50M)

7%

Cell & Gene Therapy

5%

Non-Profit Institions

15%

Tissue Engineering

8%

Academic

9%

CMOs and CROs

13%

Affiliates & Financial Institutions

3%

Service Providers

9%

Advocacy Organizations

6%

Research Organizations

4%

Medical Device

2%